Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

On October 21, 2021 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, reported the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights (Press release, Agios Pharmaceuticals, OCT 21, 2021, https://investor.agios.com/news-releases/news-release-details/agios-webcast-conference-call-third-quarter-2021-financial [SID1234591761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 5748074. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.

Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells

On October 21, 2021 Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, reported initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer (Press release, Exacis Biotherapeutics, OCT 21, 2021, View Source [SID1234591758]). The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exacis CEO Gregory Fiore, MD, commented, "We welcome CCRM as a key partner to allow us to rapidly advance our virus-free manufacturing processes to make novel NK cell products that are engineered for performance and to avoid rejection. CCRM is a recognized leader in iPSC-derived cell therapy development and manufacturing and we are thrilled to have them as a partner. Their confidence in Exacis is evidenced by the accompanying investment, by CCRM Enterprises Holdings Ltd., underscoring the unique value proposition offered by Exacis’ differentiated platform and approach to cell therapies. We look forward to partnering with CCRM’s CDMO experts to apply our mRNA based technologies to develop best-in-class products to treat challenging hematologic and solid tumors."

Cynthia Lavoie, PhD, President and CIO of CCRM Enterprises Inc. added, "We are pleased to support Exacis by way of an investment, and with our sector expertise and specialized infrastructure. This is a successful model that we have employed in the past to support promising technologies and together we will develop leading cell therapy products that utilize the substantial potential of the Exacis platform as it advances its iPSC-derived cell programs.

DYN’R Medical Systems and Mevion announce the launch of the SDX® Respiratory Gating System synchronized interface with MEVION S250i and the completion of the installation at OU Health

On October 21, 2021 DYN’R Medical Systems and Mevion Medical Systems, the leader in compact proton therapy, reported the launch of a new gating option for their joint customers (Press release, Mevion Medical Systems, OCT 21, 2021, View Source [SID1234591756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SDX Respiratory Gating system helps to protect and prevent irradiation of unaffected healthy tissues and vital organs located close to a tumor. Its cutting-edge technology enhances therapeutic accuracy and incorporates direct lung volume measurement with clear bio-visual feedback to guide the patient throughout the session. The SDX System is the most effective proton therapy respiratory monitoring solution, especially during the lung, breast and liver treatments.

Following the development and the successful conclusion of the Verification & Validation (V&V) tests completed by Mevion and DYN’R teams between 2019 and 2020, the SDX System can now be synchronized with the MEVION S250i Proton Therapy System, automatically stopping the proton beam when tumor motion is detected. Made possible by the interoperability of the Mevion Beam Gating and the SDX Gating Module interfaces, the duo provides increased accuracy of high-dose treatments while, above all, maintaining patient safety.

The NCI-Designated OU Health Stephenson Cancer Center is the first center to utilize this powerful tool, in conjunction with Mevion’s HYPERSCAN pencil beam scanning technology, to rapidly deliver sharp and robust fields to patients with breast cancer.

"The development of the synchronized interface with MEVION S250i was an important target of our business development plan" said Francois Galzin, President & CEO of DYN’R Medical Systems. "We are pleased with the quality of our partnership with Mevion, and the launch of this new solution shows the efficiency of the works realized by our teams to fight together, and each day better against cancer. It will allow all our joint customers, wherever they are based on the planet, to benefit from a high-level solution made to manage respiratory motion while increasing their patient’s safety".

"We are committed to offer fully integrated and customizable motion management systems that enable our customers to select the best tools for their center," said Armin Langenegger, Director of Production Solutions at Mevion. "The successful partnership with DYN’R and the incorporation of the SDX Gating System compliments the speed and precision of the MEVION S250i, assuring the best possible outcomes for patients."

Prior to the installation, OU Health utilized the SDX System in Manual Mode, which significantly increases the treatment’s margin precision while treating moving tumors with the DYN’R deep inspiration breath-hold solution (DIBH). Therapists have real-time access to internal organ positioning and are empowered to manually stop the beam at any moment if they note any undesirable internal motion.

DYN’R and Mevion will be exhibiting at the upcoming American Society for Radiation Oncology (ASTRO) annual meeting in Chicago, IL from October 24th to the 26th and attendees are invited to visit the companies during the event to learn more.

Longbow Immunotherapy Launches ReACT, A Novel CAR-T Platform Targeting Solid Tumors

On October 21, 2021 Longbow Immunotherapy, a newly formed biotech advancing solid tumor therapy, reported its formation and exclusive license of the ReACT platform from the Versiti Blood Research Institute (Press release, Longbow Immunotherapy, OCT 21, 2021, View Source [SID1234591755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ReACT (Re-energized adoptive cell transfer), combines CAR-T cell therapy with microbial immunotherapies, such as bacteria and oncolytic viruses, to synergistically treat solid tumors. Invented by Dr. Weiguo Cui, senior investigator, Versiti Blood Research Institute, ReACT T cells possess tumor targeting receptors as well as an added receptor that extends T cell activity when in the presence of tumor specific microbial immunotherapies. Its advantages include modification of the tumor microenvironment, localized activity, broad targeting of tumor antigens, and prevention of T cell exhaustion.

Longbow’s initial target for ReACT is bladder cancer, where Dr. Cui has engineered immune cells to express a novel CAR recognizing BCG, the standard of care in post resection bladder cancer therapy. The ReACT-BCG construct has been evaluated in a mouse model of bladder cancer, where it showed significant improvements in survival, tumor volume and immune cell markers. Dr. Cui said, "Currently, 60% of bladder cancer patients will experience recurrence within two years of tumor resection. ReACT has the potential to radically improve the prognosis for these patients."

Longbow also plans to extend the application of ReACT beyond initial bladder cancer uses, as ReACT T cells can be engineered to recognize and synergize with any bacterial immunotherapy or oncolytic virus targeting solid tumors. Kurt Rote, Co-Founder, stated, "For years, the field has been wanting to combine immunotherapy bacteria and oncolytic virus with CAR-T cells. Longbow is doing so in a novel, synergistic fashion, and is dedicated to getting this promising treatment to patients."

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

On October 21, 2021 Mablink Bioscience S.A.S. a biotechnology company developing a pipeline of ADC based on its proprietary PSARlink drug-linker technology and Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat cancers with high unmet needs reported that they entered into a Licensing Agreement (Press release, Mablink Bioscience, OCT 21, 2021, View Source [SID1234591752]). Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Elands, CEO of Emergence Therapeutics said: "Mablink Bioscience’s technology, PSARlink, which is based on a hydrophilic linker using a polysarcosine arm, enabled us to design a Nectin-4 ADC loaded with the cytotoxic agent of our choice, whilst retaining the antibody’s pharmacological properties. This technology has the potential to widen the therapeutic index of an ADC and to make our Nectin-4 ADC a best-in-class. The preclinical data we obtained so far are very encouraging in this regard." Jean-Guillaume Lafay, CEO of Mablink Bioscience added: "We have developed a unique technology that we believe solves the core issue that impaired so many ADC developments. Grafting cytotoxic molecules to an Antibody usually creates a rather hydrophobic ADC, which is correlated with poor pharmacological properties (low drug-exposure and general toxicity issues). While Mablink Bioscience develops its own drug candidates targeting several difficult-to-treat cancers, we are delighted to be joined by Emergence Therapeutics in our effort to develop the 3rd generation of ADCs and to bring new, more efficient, therapeutic options to cancer patients."

Pursuant to the agreement, Mablink Bioscience is entitled to receive milestone and royalty payments, based on the development of the Nectin-4 ADC.

About PSARlink

PSARlink drug-linkers are a chemical physical link that can be placed between an antibody and a chosen cytotoxic molecule to be delivered into tumor cells. PSARlink’s unique structure "masks" the cytotoxic molecules, especially hydrophobic compounds, and provides a "stealthy" property to such antibody drug conjugates, enabling them to stay longer in the body, giving them more time to destroy tumor cells. At the same time, making ADC stealth avoids most of the damage typically caused by such molecules to healthy cells: PSARlink-based ADC are better tolerated. These improvements translate into a 10-fold increase of the therapeutic index observed in animal models, a potentially game changing factor for future clinical success.